Loading clinical trials...
Loading clinical trials...
A Phase I and Pilot Study Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2
Conditions
Interventions
NT-I7
Placebo
+4 more
Start Date
July 31, 2021
Primary Completion Date
April 30, 2022
Completion Date
April 30, 2022
Last Updated
August 5, 2021
NCT07221162
NCT06082518
NCT06631287
NCT05141058
NCT06679140
NCT06417762
Lead Sponsor
Washington University School of Medicine
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions